Coya Therapeutics announces positive results of a double-blind study of subcutaneous low-dose interleukin-2 in Alzheimer’s disease
- Coya Therapeutics presented results from a Phase 2 trial of low-dose interleukin-2 (LD IL-2) in Alzheimer's patients at the CTAD24 conference.
- The study involved 38 participants, comparing two dosing regimens of LD IL-2 against placebo over a 21-week period.
- Primary endpoint of safety was met, with LD IL-2 showing significant expansion of regulatory T cell populations and improvements in cerebrospinal fluid biomarkers.
- The q4wks dosing regimen showed promising trends in stabilizing cognitive function, while the q2wks regimen did not exhibit similar benefits.
Read more
